DexCom R&D decreased by 2.0% to $145.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from $145.20M to $145.30M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 3.7% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $129.10M | $128.80M | $149.80M | $135.90M | $121.70M | $110.30M | $116.30M | $119.00M | $119.30M | $131.40M | $136.10M | $141.50M | $136.00M | $135.40M | $139.50M | $145.20M | $148.20M | $157.50M | $148.20M | $145.30M |
| QoQ Change | — | -0.2% | +16.3% | -9.3% | -10.4% | -9.4% | +5.4% | +2.3% | +0.3% | +10.1% | +3.6% | +4.0% | -3.9% | -0.4% | +3.0% | +4.1% | +2.1% | +6.3% | -5.9% | -2.0% |
| YoY Change | — | — | — | — | -5.7% | -14.4% | -22.4% | -12.4% | -2.0% | +19.1% | +17.0% | +18.9% | +14.0% | +3.0% | +2.5% | +2.6% | +9.0% | +16.3% | +6.2% | +0.1% |